Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact

References

• Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? Orphanet J Rare Dis. 2017 Jan 5; 12(1):1.
   PubMedGoogle Scholar
• Kacetl J, Maresova P, Maskuriy R, et al. Ethical questions linked to rare diseases and orphan drugs - a systematic review. Risk Manag Healthc Policy. 2020;13:2125–2148.
   PubMed Web of Science ®Google Scholar
• Mayrides M, Ruiz de Castilla EM, Szelepski S. A civil society view of rare disease public policy in six Latin American countries. Orphanet J Rare Dis. 2020 Feb 27; 15(1):60.
   PubMed Web of Science ®Google Scholar
• Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017 Feb;21(7):1–204.
   PubMed Web of Science ®Google Scholar
• Jorgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020;8(1):1715536.
   PubMedGoogle Scholar
• Michelsen S, Nachi S, Van Dyck W, et al. Barriers and opportunities for implementation of outcome-Based spread payments for high-cost, one-shot curative therapies. Front Pharmacol. 2020;11:594446.
   PubMed Web of Science ®Google Scholar
• Kanavos P, Fontrier AM, Gill J, et al. Does external reference pricing deliver what it promises? Evidence on its impact at national level. Eur J Health Econ. 2020 Feb;21(1):129–151.
   PubMed Web of Science ®Google Scholar
• Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs–evidence from twenty-five major markets in the 1990s. Health Econ. 2005 Mar;14(3):269–292.
   PubMed Web of Science ®Google Scholar
• Remuzat C, Urbinati D, Mzoughi O, et al. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015:3.
   Google Scholar
• Gammie T, Lu CY, Babar ZU. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS One. 2015;10(10):e0140002.
   PubMed Web of Science ®Google Scholar
• Giannuzzi V, Conte R, Landi A, et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis. 2017 Apr 3 12(1):64.
   PubMedGoogle Scholar
• Czech M, Baran-Kooiker A, Atikeler K, et al. A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries. Front Public Health. 2019;7:416.
   PubMed Web of Science ®Google Scholar
• Malinowski KP, Kawalec P, Trabka W, et al. Reimbursement legislations and decision making for orphan drugs in central and Eastern European Countries. Front Pharmacol. 2019;10:487.
   PubMed Web of Science ®Google Scholar
• Zamora B, Maignen F, O’Neill P, et al. Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis. 2019 May 3; 14(1):95.
   PubMedGoogle Scholar
• Kawalec P, Sagan A, Pilc A. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe. Orphanet J Rare Dis. 2016 Sep 6; 11(1):122.
   PubMedGoogle Scholar
• Gronde TV, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: a systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One. 2017;12(8):e0182613.
   PubMed Web of Science ®Google Scholar
• Godman B, Bucsics A, Vella Bonanno P, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018;6:328.
   PubMed Web of Science ®Google Scholar
• Cote A, Keating B. What is wrong with orphan drug policies? Value Health. 2012 Dec;15(8):1185–1191.
   PubMed Web of Science ®Google Scholar
• Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014 May;15(4):335–340.
   PubMed Web of Science ®Google Scholar
• Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan. 2009 Jan;24(1):63–71.
   PubMed Web of Science ®Google Scholar
• Do N, Oh J, Lee JS. Moving toward universal coverage of health insurance in Vietnam: barriers, facilitating factors, and lessons from Korea. J Korean Med Sci. 2014 Jul;29(7):919–925.
   PubMed Web of Science ®Google Scholar
• Bae EY, Hong JM, Kwon HY, et al. Eight-year experience of using HTA in drug reimbursement: South Korea. Health Policy. 2016 Jun;120(6):612–620.
   PubMed Web of Science ®Google Scholar
• Bae E-Y, Kim HJ, Lee H-J, et al. Role of economic evidence in coverage decision-making in South Korea. PLoS One. 2018;13(10):e0206121.
   PubMed Web of Science ®Google Scholar
• Yoo SL, Kim DJ, Lee SM, et al. Improving patient access to new drugs in South Korea: evaluation of the national drug formulary system. Int J Environ Res Public Health. 2019 Jan 21;16(2). 10.3390/ijerph16020288
   Web of Science ®Google Scholar
• Lee SH, Yoo SL, Bang JS, et al. Patient accessibility and budget impact of orphan drugs in South Korea: long-term and real-world data analysis (2007-2019). Int J Environ Res Public Health. 2020 Apr 26. 17(9)
   Web of Science ®Google Scholar
• Kim S, Cho H, Kim J, et al. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways. Expert Rev Pharmacoecon Outcomes Res. 2021 Feb;21(1):119–126.
   PubMed Web of Science ®Google Scholar
• Service HIRA. Hira notification: detailed evaluation criteria for new drugs subject to negotiation. 2020. [cited2021 Aug 1]. Available from: http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000.
   Google Scholar
• Mardiguian S, Stefanidou M, Sheppard F. Trends and key decision drivers for rejecting an orphan drug submission across five different HTA agencies. Value Health. 2014 Nov;17(7):A438.
   PubMed Web of Science ®Google Scholar
• McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005 Oct 29; 331(7523):1016–1019.
   PubMedGoogle Scholar
• McCabe C, Edlin R, Round J. Economic considerations in the provision of treatments for rare diseases. Adv Exp Med Biol. 2010;686:211–222.
   PubMed Web of Science ®Google Scholar